A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome

Affiliations

¹ Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Australia.
² Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
³ Molecular Oncology and Cancer Immunology Epworth Healthcare, East Melbourne, Victoria, Australia.

T Papps et al. Br J Dermatol. 2020 Feb.

. 2020 Feb;182(2):497-498.

doi: 10.1111/bjd.18522. Epub 2019 Oct 13.

¹ Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Australia.
² Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
³ Molecular Oncology and Cancer Immunology Epworth Healthcare, East Melbourne, Victoria, Australia.

No abstract available

References

1. Duvic M, Talpur R, Ni X et al. Clinical trials and observations - phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, sAHA) for refractory cutaneous t-cell lymphoma. Blood 2007; 109:31-9.
1. Piekarz RL, Frye R, Turner M et al. A multi-institutional phase II trial of the HDAC inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27:410-7.
1. Duvic M, Dummer R, Becker JC et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-Cell lymphoma: results of a phase II trial. Eur J Cancer 2013; 48:386-94.
1. Dickinson M, Johnstone R, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010; 28 (Suppl 1):S3-20.
1. Hughes CF, Khot A, McCormack C et al. The lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015; 125:71-81.